Stock fact sheet · data as of

QHSLab, Inc. (USAQ): fair value, margin of safety and Wheel Score

Healthcare · Medical - Devices · United States · High Growth

Close0.4600
GLS fair value1.135 of 9 models
Margin of safety+59%price below fair value
Wheel Score39No optionscapped: no options
Health5/9Piotroski F-score
Moat4.7/10GLS 10-year score
Market cap$7M4k shares a day
Implied vol.-no listed options
P/E13.2EPS 0.03
Dividend yieldnone
Beta0.65moves less than the market
Next earnings17 Nov 2026in 32 days

Is USAQ undervalued?

QHSLab, Inc. (USAQ) closed at 0.4600 on 16 Oct 2026. The GLS average fair value - the simple average of the 5 valuation models that produced a positive number - is 1.13, which puts the price 59% below it. 3 of the 5 models value the shares above the current price. A gap this wide is rare in our universe of ~7,400 US stocks and is exactly what the Value part of the Wheel Score rewards; it is also where the question "why is it this cheap?" matters most.

The 5 models disagree widely: Graham Number gives 0.2852 while GLS Growth gives 2.13. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.

The nightly engine files USAQ under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.

Nine valuation models for USAQ

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF--Present value of the projected free cash flows, discounted at the cost of capital; no value tonight
Graham Number0.2852-38%The most a defensive investor pays for the earnings and book value per share
Graham Growth1.99+334%Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields
Lynch0.8716+89%EPS × the earnings growth rate (PEG of 1), growth capped at 25%
GLS Growth2.13+364%EPS compounded ten years at the blended growth rate, discounted back at 15% a year
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV0.3874-16%Earnings power value: current EPS capitalised at 9% with no growth
Zombie (liquidation)0.0224-95%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target0.0000-100%Analysts' average 12-month price target. Not in the average

Quality and financial health

Financial health is average - USAQ passes 5 of the nine Piotroski tests, which falls one point short of the Sunday Scan's "6 or more" rule. The Financials tab on the Quote page shows which tests fail. The GLS Moat score is low at 4.7 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.

Returns on capital are high - ROIC 27.8%, ROE 28.1%, ROA 21.1% - with debt at 0.01 times equity and negative free cash flow.

QHSLab, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Shipping and Handling 62%, Subscription Revenue 38% (quarter Q2 FY2026).

Institutional ownership scores 5/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score5 / 9ROIC27.8%
GLS Moat4.7 / 10ROE28.1%
Debt / equity0.01ROA21.1%
Free-cash-flow yield-1.6%Payout ratio6%
Institutions5 / 10Insiders · Congress5 · 5 / 10

Wheel Score 39: No options

USAQ has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (39 here). The valuation and quality numbers still apply to owning the shares outright.

Volume runs at 4k shares a day on a market cap of $7M, with a beta of 0.65 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.

PartPointsFrom
Value25 / 2559% margin of safety
Health11 / 20Piotroski 5/9
Moat7 / 15moat 4.7/10
Premium0 / 20no option data
Stability6 / 204k shares/day, $7M cap, beta 0.65

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 17 Nov 2026, 32 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Devices

The 12 companies below are the closest to QHSLab, Inc. by market cap within the Medical - Devices industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
KLYG
Kelyniam Global, Inc.
0.1200--27No options$6M
BMRA
Biomerica, Inc.
1.88--23No options$9M
NVNO
enVVeno Medical Corporation
7.933.46-129%10No options$6M
NMTC
NeuroOne Medical Technologies Corporation
1.04--36Weak$9M
CTSO
Cytosorbents Corporation
3.06--29Weak$10M
LFWD
Lifeward Ltd.
6.06--28Weak$10M
STME
Stimcell Energetics, Inc.
0.2300--19No options$5M
INBS
Intelligent Bio Solutions Inc.
1.44--22No options$5M
SINT
Sintx Technologies, Inc.
1.82--27No options$12M
PLSM
Pulsenmore Ltd. Ordinary Shares
1.82--32No options$12M
IRIX
IRIDEX Corporation
0.8244--33Weak$14M
PAVM
PAVmed Inc.
2.29--24No options$15M

⚖ Compare USAQ with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about USAQ

Is USAQ undervalued right now?

By the GLS models, yes: at 0.4600 the stock is 59% below the average fair value of 1.13 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.

What is the Wheel Score of USAQ and what does it mean?

USAQ has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".

What is the GLS fair value for USAQ?

1.13 per share as of 16 Oct 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does QHSLab, Inc. report earnings next?

The next earnings report is due on 17 Nov 2026, 32 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does USAQ have listed options, and how liquid are they?

No. The nightly options snapshot found no listed contracts on USAQ, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.